Key result
Diabetic myocardium shows ~4-fold higher acylcarnitines, reversible with insulin or iPLA2 inactivation.
Answers are grounded in this paper and cite their sources.
Diabetic cardiomyopathy is the result of maladaptive changes in energy homeostasis. However, the biochemical mechanisms underlying dysfunctional lipid metabolism in diabetic myocardium are incompletely understood. Herein, we exploit shotgun lipidomics to demonstrate a 4-fold increase in acylcarnitines in diabetic myocardium, which was reversible upon insulin treatment. Analysis of acylcarnitine molecular species in myocardium unexpectedly identified acylcarnitine molecular species containing a mass shift of 16 amu in comparison to the anticipated molecular species. Synthesis of 3-hydroxy acylcarnitine identified the natural products as the 3-hydroxylated acylcarnitines through comparisons of diagnostic fragmentation patterns of synthetic and naturally occurring constituents using tandem mass spectrometry. Diabetes induced an increase of both calcium-independent phospholipase A(2) (iPLA(2)) mRNA and iPLA(2) activity in rat myocardium. Cardiac ischemia in myocardium genetically engineered to overexpress iPLA(2) dramatically increased the amount of acylcarnitine present in myocardium. Moreover, mechanism-based inactivation of iPLA(2) in either wild-type or transgenic myocardium ablated a substantial portion of the acylcarnitine increase. Collectively, these results identify discrete insulin remediable abnormalities in mitochondrial fatty acid processing in diabetic myocardium and identify iPLA(2) as an important enzymatic contributor to the pool of fatty acids that can be used for acylcarnitine synthesis and energy production in myocardium.
No takes yet. Share an insight, caveat, or question.
Su et al. (2005) studied Diabetic cardiomyopathy. Insulin treatment and mechanism-based iPLA2 inactivation vs. Untreated diabetic or wild-type myocardium was evaluated on Myocardial acylcarnitine and 3-hydroxy acylcarnitine accumulation (4-fold increase in diabetic myocardium). Diabetic myocardium exhibited a 4-fold increase in acylcarnitines that was reversible with insulin treatment and substantially ablated by iPLA2 inactivation.
Synapse has enriched 10 related papers. Consider them for comparative context: